In 2018, the global market for medical and research grade collagen was valued at US$ 495.4 million and is projected to experience a compound annual growth rate (CAGR) of 6.7% from 2019 to 2027, reaching an estimated US$ 884.2 million by the end of the forecast period.
Collagen is the most prevalent protein in the human body, primarily found in fibrous tissues such as skin, ligaments, tendons, corneas, blood vessels, bones, cartilage, and intervertebral discs. This type of collagen, specifically designated for medical and research purposes, is extensively utilized in various medical fields, including wound healing, tissue engineering, reconstructive surgeries, bone grafting, and cosmetic procedures. Its biocompatibility and low immunogenicity make it an ideal material for these applications. Collagen also exhibits excellent haemostatic properties, aiding in the wound healing process. In cell culture applications, collagen supports cell proliferation through its lattice structures and cell-binding domains, making it a vital biomaterial in the medical sector. The increasing number of regenerative surgeries aimed at treating skin cancers, burn injuries, congenital defects, and other medical conditions is expected to significantly drive the demand for medical and research grade collagen, thereby fostering market growth.
The global market for medical and research grade collagen is categorized based on source, product, and application. The sources include bovine, porcine, poultry, marine, and others. In terms of product types, the market is divided into gelatin, hydrolyzed collagen, native collagen, and additional variants. Notably, the hydrolyzed collagen segment is anticipated to witness the highest growth rate during the forecast period, primarily due to its increasing use in medical applications. Hydrolyzed collagen supplements are known to alleviate joint pain and enhance athletic performance. Additionally, films made from hydrolyzed collagen serve as tissue adhesives for suture replacements, owing to their chemical similarity to connective tissues and their ability to bind tissue fluids. This form of collagen is gaining popularity as a protein alternative. In medical contexts, it is utilized for joint recovery, cancer therapies, and post-operative care.
Cardiovascular diseases (CVD) have emerged as one of the leading causes of mortality among both men and women in the United States in recent years. As the population ages, the costs and prevalence of care associated with CVD conditions, such as heart failure and stroke, are expected to rise significantly in the coming decades. These trends, coupled with supportive government initiatives, are contributing to the expansion of the global medical and research grade collagen market.
Key players in the global medical and research grade collagen market include DSM, Collagen Solutions Plc., Croda International Plc., Advanced Biomatrix Inc., Collagen Matrix, Inc., Cologenesis Healthcare Pvt. Ltd., Innocoll Holdings Plc., Integra LifeSciences Corporation, Nitta Gelatin NA Inc., and Rousselot, among others.
The overall size of the global medical and research grade collagen market has been determined through a combination of primary and secondary research methods. The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data related to the market. Additionally, numerous primary interviews are conducted with industry participants and experts to validate the findings and analyses. Participants typically include industry professionals such as vice presidents, business development managers, market intelligence managers, and national sales managers, as well as external consultants like valuation experts, research analysts, and key opinion leaders specializing in the medical and research grade collagen sector.